Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bio Technology General - BTGC -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (1917)	8/23/1999 1:11:00 PM
From: Liatris Spicata	Respond to of 2028

Another take on this announcement: biz.yahoo.com

To: Jim Oravetz who wrote (1917)	8/30/1999 12:52:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 2028

DJ Bio-Tech Genl Starts Clinical Trial Of BioHy In Germany ISELIN, N.J. (Dow Jones)--Bio-Technology General Corp. (BTGC) started clinical trial of BioHy, a sodium hyaluronate product, for the treatment of pain associated with osteoarthritis of the knee in Germany. In a press release Friday, the company said a randomized, double-blind study will compare BioHy with the current lead commercial product in the European viscoelastic market. The study will enroll 250 patients for a series of intra-articular injections of BioHy or the competitor's product into the knee. Bio-Technology expects to complete the study in the first half of 2000. Bio-Technology plans to file for approval to market BioHy in Europe, after showing the safety and efficacy of the product. The company said injecting sodium hyaluronate into the knee has been shown to reduce pain associated with osteoarthritis of the knee by increasing elastoviscosity within the joint. Nasdaq-listed shares of the biopharmaceutical company recently traded at 10 1/8, down 3/16 or 1.8%, on composite volume of 174,900 shares. Average daily volume is 613,481 shares.